NCT03359460View on ClinicalTrials.gov

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

August 29, 2019

Study Completion Date

November 17, 2019

Conditions
Myelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeSecondary Myelodysplastic SyndromeTherapy-Related Myelodysplastic Syndrome
Interventions
DRUG

Ibrutinib

Given PO

DRUG

Lenalidomide

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (2)

Pharmacyclics LLC.
Celgene
All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

collaborator

Celgene

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Brian Jonas

OTHER

NCT03359460 - Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter